Theseus Pharmaceuticals, Inc. (THRX)

NASDAQ: THRX · IEX Real-Time Price · USD
8.71
-0.04 (-0.46%)
Jan 27, 2022 3:59 PM EST - Market open

Company Description

Theseus Pharmaceuticals is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies.

Our development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. Resistance mutations limit the efficacy of existing targeted therapies by rendering tumor cells unresponsive to drugs, and therefore present a critical challenge in cancer treatment today.

Our goal is to develop “pan-variant” kinase inhibitors—inhibitors that target all major cancer causing and drug resistance mutations in clinically significant protein kinases.

Our lead product candidate, THE-630, is a pan-variant inhibitor of all major classes of activating and resistance mutations of the KIT kinase for the treatment of gastrointestinal stromal tumors, or GIST, a type of cancer characterized by oncogenic activation of KIT.

THE-630 is derived from intellectual property exclusively licensed to us by ARIAD Pharmaceuticals. We plan to submit an Investigational New Drug application to the U.S. Food and Drug Administration in the fourth quarter of 2021 for the evaluation of THE-630 in patients with advanced GIST whose disease has developed resistance to prior KIT-targeting therapies

Theseus Pharmaceuticals, Inc.
CountryUnited States
Founded2017
IPO DateOct 7, 2021
IndustryBiotechnology
SectorHealth Care
Employees16
CEOTimothy P. Clackson, Ph.D.

Contact Details

Address:
245 Main Street
Cambridge, MA 02142
United States
Phone857-400-9491
Websitetheseusrx.com

Stock Details

Ticker SymbolTHRX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$16.00
CIK Code1745020

Key Executives

NamePosition
Dr. Iain D. Dukes D.Phil., DPHIL, M.A.Co-Founder and Chairman
Dr. William C. Shakespeare Ph.D.Co-Founder and President of Research & Development
Dr. David C. Dalgarno Ph.D.Co-Founder, Senior Vice President and Chief Technology Officer
Dr. Victor M. Rivera Ph.D.Co-Founder, Senior Vice President and Chief Scientific Officer
Dr. Timothy P. Clackson Ph.D.Chief Executive Officer, President and Director
Wei-Sheng Huang Ph.D.Co-Founder and Vice President of Chemistry
Bradford D. DahmsChief Financial officer
Alicja Januszewicz Ph.D.Senior Vice President of People and Culture
Dr. David P. Kerstein M.D.Chief Medical Officer
Dr. Nachu Narasimhan Ph.D.Senior Vice President of Drug Metabolism and Preclinical Safety

Latest SEC Filings

DateTypeTitle
Jan 21, 20224Statement of changes in beneficial ownership of securities
Jan 21, 20224Statement of changes in beneficial ownership of securities
Jan 13, 20224Statement of changes in beneficial ownership of securities
Jan 13, 20224Statement of changes in beneficial ownership of securities
Jan 10, 20228-KCurrent report
Dec 22, 20214Statement of changes in beneficial ownership of securities
Dec 22, 20214Statement of changes in beneficial ownership of securities
Nov 18, 2021SC 13D/AGeneral statement of acquisition of beneficial ownership
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 15, 20218-KCurrent report
View All SEC Filings